SPOTLIGHT: Once-daily Seroquel OK'd


AstraZeneca won FDA approval for a new, once-daily version of Seroquel, significantly extending the product life of a drug that earned $3.4 billion last year. The schizophrenia drug is AstraZeneca's second biggest seller. The new version will be under patent until 2017. Report